Cancer Genetics (CGIX) Stock Price
Cancer Genetics Price
Revenue has compounded at 14.8% per year over the past 14 years to 5.75 M USD. Cancer Genetics's net margin stands at -139.1%, down from -58.4% several years earlier.
Cancer Genetics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Cancer Genetics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cancer Genetics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cancer Genetics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Cancer Genetics Price |
|---|
Cancer Genetics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Cancer Genetics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESk |
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.00 | 1.00 | 1.00 | 2.00 | 3.00 | 4.00 | 6.00 | 10.00 | 18.00 | 27.00 | 29.00 | 27.00 | 7.00 | 5.00 | 79.00 | 112.00 |
| – | -50.00 | – | 100.00 | 50.00 | 33.33 | 50.00 | 66.67 | 80.00 | 50.00 | 7.41 | -6.90 | -74.07 | -28.57 | 1,480.00 | 41.77 |
| 100.00 | 200.00 | 200.00 | 100.00 | 66.67 | 50.00 | 16.67 | 10.00 | 16.67 | 33.33 | 37.93 | 29.63 | 42.86 | 40.00 | 40.00 | 40.00 |
| 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 3.00 | 9.00 | 11.00 | 8.00 | 3.00 | 2.00 | 31.60 | 44.80 |
| -1.00 | -2.00 | -4.00 | -6.00 | -8.00 | -7.00 | -8.00 | -19.00 | -21.00 | -16.00 | -20.00 | -20.00 | -6.00 | -8.00 | – | – |
| -50.00 | -200.00 | -400.00 | -300.00 | -266.67 | -175.00 | -133.33 | -190.00 | -116.67 | -59.26 | -68.97 | -74.07 | -85.71 | -160.00 | – | – |
| -2.00 | -3.00 | -7.00 | -8.00 | -19.00 | -6.00 | -12.00 | -16.00 | -20.00 | -15.00 | -20.00 | -20.00 | -6.00 | -8.00 | – | – |
| – | 50.00 | 133.33 | 14.29 | 137.50 | -68.42 | 100.00 | 33.33 | 25.00 | -25.00 | 33.33 | – | -70.00 | 33.33 | – | – |
| 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 | 170.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Cancer Genetics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cancer Genetics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cancer Genetics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Cancer Genetics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cancer Genetics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Cancer Genetics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Cancer Genetics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Cancer Genetics business model & stock analysis
Cancer Genetics SWOT Analysis
Strengths
Cancer Genetics Inc (CGI) has developed a strong reputation in the field of genetic testing for cancer. Their expertise and experience contribute to their credibility in the industry.
CGI has a diverse portfolio of genetic tests, allowing them to serve a wide range of cancer types and provide personalized treatment options for patients.
The company has established collaborations with leading research institutes and healthcare organizations, enhancing their access to data and resources for ongoing advancements in genetic testing.
Weaknesses
CGI faces limitations in terms of scalability as genetic testing requires specialized equipment and expertise. This may hinder their ability to rapidly expand their operations.
The high cost associated with genetic testing may limit the accessibility of CGI's services, especially in regions with limited healthcare resources or inadequate insurance coverage.
The regulatory landscape for genetic testing is continually evolving, posing challenges for CGI to comply with changing guidelines and standards.
Opportunities
The increasing prevalence of cancer worldwide creates a growing market for genetic testing services. CGI can capitalize on this opportunity by expanding their reach and offering innovative testing solutions.
Advancements in technology, such as next-generation sequencing and artificial intelligence, provide CGI with the opportunity to enhance the accuracy and efficiency of their testing processes.
Collaboration with pharmaceutical companies and clinicians can open doors for CGI to contribute to the development of targeted therapies and personalized medicine based on genetic insights.
Threats
Competition in the genetic testing sector is intensifying, with the emergence of new players and technological advancements. CGI needs to continuously innovate and differentiate themselves to maintain their market share.
Changes in reimbursement policies and regulations may impact the financial viability of CGI's services, potentially leading to decreased profitability.
Consumer concerns over privacy and the ethical implications of genetic testing may discourage potential customers from utilizing CGI's services.
Cancer Genetics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Cancer Genetics historical P/E ratio, EBIT multiple, and P/S ratio
Cancer Genetics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Cancer Genetics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Cancer Genetics stock splits
Frequently asked questions about Cancer Genetics
Cancer Genetics Inc is a biotechnology company that specializes in developing personalized diagnostics and genomic tests for cancer patients. Their business model revolves around providing advanced molecular information and genetic testing services to healthcare providers, pharmaceutical companies, and research institutions. By utilizing their expertise in genomic profiling and data analysis, Cancer Genetics Inc aims to improve patient care by delivering precise and comprehensive insights into the genetic makeup of cancer. With a focus on precision medicine, the company strives to enhance treatment decision-making processes and facilitate the development of targeted therapies for various types of cancer.
Cancer Genetics stock
Cancer Genetics Peer Group
Cancer Genetics Ticker
Cancer Genetics FIGI
All fundamentals and in-depth analysis of Cancer Genetics
Our stock analysis for Cancer Genetics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cancer Genetics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.